Reduced hypoglycaemia using liver-targeted insulin in individuals with type 1 diabetes.

Ruth S WeinstockBruce W BodeSatish K GargDavid C KlonoffCaroline El SanadiW Blair GehoDouglas B MuchmoreMarc S Penn

Published in: Diabetes, obesity & metabolism (2022)

Our study shows that liver-targeted BoI safely decreases HEv and symptoms without compromising glucose control. We further show that with initiation of liver-targeted BoI, the BBR can be safely increased by significantly lowering BaI dosing, leading to greater BoI usage.

Keyphrases

type diabetes
cancer therapy
drug delivery
blood pressure
depressive symptoms
sleep quality